These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. A Fast and Clean BTK Inhibitor. Gabizon R; London N J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033 [TBL] [Abstract][Full Text] [Related]
23. Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis. Pery N; Rizvi NB; Shafiq MI J Mol Model; 2020 Aug; 26(9):235. PubMed ID: 32808204 [TBL] [Abstract][Full Text] [Related]
24. SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl. Patel HV; Tzeng SR; Liao CY; Chen SH; Cheng JW Proteins; 1997 Dec; 29(4):545-52. PubMed ID: 9408950 [TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors. Wahl MI; Fluckiger AC; Kato RM; Park H; Witte ON; Rawlings DJ Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11526-33. PubMed ID: 9326643 [TBL] [Abstract][Full Text] [Related]
27. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018). Feng Y; Duan W; Cu X; Liang C; Xin M Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232 [TBL] [Abstract][Full Text] [Related]
28. A mechanism for localized dynamics-driven activation in Bruton's tyrosine kinase. Qiu S; Liu Y; Li Q R Soc Open Sci; 2021 Aug; 8(8):210066. PubMed ID: 34457331 [TBL] [Abstract][Full Text] [Related]
29. Structure of the PH domain and Btk motif from Bruton's tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. Hyvönen M; Saraste M EMBO J; 1997 Jun; 16(12):3396-404. PubMed ID: 9218782 [TBL] [Abstract][Full Text] [Related]
31. T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Xia S; Liu X; Cao X; Xu S Cell Mol Immunol; 2020 Oct; 17(10):1042-1052. PubMed ID: 31431692 [TBL] [Abstract][Full Text] [Related]
32. Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity. Cho H; Lee E; Kwon HA; Seul L; Jeon HJ; Yu JH; Ryu JH; Jeon R Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33113810 [TBL] [Abstract][Full Text] [Related]
33. A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Quek LS; Bolen J; Watson SP Curr Biol; 1998 Oct; 8(20):1137-40. PubMed ID: 9778529 [TBL] [Abstract][Full Text] [Related]
34. A potent seven-membered cyclic BTK (Bruton's tyrosine Kinase) chiral inhibitor conceived by structure-based drug design to lock its bioactive conformation. Lopez-Tapia F; Lou Y; Brotherton-Pleiss C; Kuglstatter A; So SS; Kondru R Bioorg Med Chem Lett; 2019 May; 29(9):1074-1078. PubMed ID: 30857747 [TBL] [Abstract][Full Text] [Related]
35. A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells. Tomlinson MG; Woods DB; McMahon M; Wahl MI; Witte ON; Kurosaki T; Bolen JB; Johnston JA BMC Immunol; 2001; 2():4. PubMed ID: 11410123 [TBL] [Abstract][Full Text] [Related]
36. Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases. Ma B; Bohnert T; Otipoby KL; Tien E; Arefayene M; Bai J; Bajrami B; Bame E; Chan TR; Humora M; MacPhee JM; Marcotte D; Mehta D; Metrick CM; Moniz G; Polack E; Poreci U; Prefontaine A; Sheikh S; Schroeder P; Smirnakis K; Zhang L; Zheng F; Hopkins BT J Med Chem; 2020 Nov; 63(21):12526-12541. PubMed ID: 32696648 [TBL] [Abstract][Full Text] [Related]
37. Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages. Nyhoff LE; Clark ES; Barron BL; Bonami RH; Khan WN; Kendall PL J Immunol; 2018 Apr; 200(7):2352-2361. PubMed ID: 29483358 [TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase. Buhl AM; Cambier JC J Immunol; 1999 Apr; 162(8):4438-46. PubMed ID: 10201980 [TBL] [Abstract][Full Text] [Related]